Neuromodulation of Central Sensory Integration to Improve Postural Control

Inclusion criteria for breast, ovarian and endometrial cancer survivors: * Women aged 50-85 years * Breast, ovarian and/or endometrial cancer survivors, stages I-IV * Completion of taxane chemotherapy treatment. Taxane combined with a history of anthracycline and/or cyclophosphamide is permitted. Active anti-estrogen therapy is permitted. Receiving platin based agents is permitted. * Ability to walk without an assistive device * Ability to speak and read English * Without neurological disease, aside from chemotherapy induced peripheral neuropathy (CIPN) or chemotherapy related cognitive dysfunction (CRCD) * No history of a other cancer, with the exception that non-melanoma skin cancers are permitted * Own a device with capability to sync the Fitbit Inclusion criteria for older cancer-free women: * Women aged 50-85 years * Ability to walk without an assistive device * Ability to speak and read English * Without neurological disease * No history of cancer * Own a device with capability to sync the Fitbit Inclusion for older, taxane-treated breast, ovarian, and endometrial cancer survivors (OTTBCS) performing a single visit: * Women aged 50-85 years * Breast, ovarian and/or endometrial cancer survivors, stages I-IV * Completion of taxane chemotherapy treatment. Taxane combined with a history of anthracycline and/or cyclophosphamide is permitted. Active anti-estrogen therapy is permitted. Receiving platin based agents is permitted. * Ability to walk without an assistive devi…